

CITATION REPORT

List of articles citing

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis

DOI: 10.1186/s12916-019-1344-3
BMC Medicine, 2019, 17, 117.

Source: <https://exaly.com/paper-pdf/72952130/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
13	Generating comparative evidence on new drugs and devices after approval. <i>Lancet, The</i> , 2020 , 395, 998-1010	10.1	23
12	Benefits and limitations of real-world evidence: lessons from mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2021 , 17, 965-977	3.6	10
11	An overview of IND, NDA, approval agencies and FDA post-marketing surveillance. 2021 , 267-273		
10	Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. <i>JAMA Network Open</i> , 2021 , 4, e217063	10.4	3
9	US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018. <i>Clinical Trials</i> , 2021 , 18, 488-499	2.2	7
8	Can we learn lessons from the FDA's approval of aducanumab?. <i>Nature Reviews Neurology</i> , 2021 , 17, 715-722	15	17
7	U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.		1
6	Challenges in confirming drug effectiveness after early approval. <i>Science</i> , 2021 , 374, 1205-1207	33.3	2
5	New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence.. <i>Drug Safety</i> , 2022 ,	5.1	0
4	Strategies to Manage Drugs and Devices Approved Based on Limited Evidence: Results of a Modified Delphi Panel.. <i>Clinical Pharmacology and Therapeutics</i> , 2022 ,	6.1	
3	Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis.. <i>Clinical Trials</i> , 2022 , 17407745221093567	2.2	
2	Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.. <i>JAMA Network Open</i> , 2022 , 5, e2212454	10.4	2
1	Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. <i>Clinical Pharmacology and Therapeutics</i> ,	6.1	0